Get the Stockscreener App
13.20
1.49%
-0.20
After Hours:
13.06
-0.14
-1.06%
Hutchmed China Limited Adr stock is traded at $13.20, with a volume of 30,224.
It is down -1.49% in the last 24 hours and down -8.46% over the past month.
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.
See More
Previous Close:
$13.40
Open:
$13.17
24h Volume:
30,224
Relative Volume:
0.88
Market Cap:
$2.27B
Revenue:
$603.63M
Net Income/Loss:
$468.71M
P/E Ratio:
4.9217
EPS:
2.682
Net Cash Flow:
$-59.92M
1W Performance:
-2.08%
1M Performance:
-8.46%
6M Performance:
-12.58%
1Y Performance:
-8.08%
1-Day Range:
$13.13
$13.30
1-Week Range:
$13.13
$13.88
52-Week Range:
$11.51
$19.50
Hutchmed China Limited Adr Stock (HCM) Company Profile
Compare HCM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HCM
Hutchmed China Limited Adr
|
13.20 | 2.30B | 603.63M | 468.71M | -59.92M | 2.682 |
|
ZTS
Zoetis Inc
|
126.41 | 55.52B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.63 | 49.79B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.08 | 44.93B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.34 | 36.21B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
496.19 | 21.65B | 3.08B | 1.24B | 1.07B | 25.61 |
Hutchmed China Limited Adr Stock (HCM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-22-25 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| May-13-25 | Downgrade | HSBC Securities | Buy → Hold |
| Nov-24-23 | Upgrade | Deutsche Bank | Hold → Buy |
| May-04-22 | Downgrade | Deutsche Bank | Buy → Hold |
| Sep-22-21 | Downgrade | Goldman | Buy → Neutral |
| Aug-03-21 | Initiated | Jefferies | Buy |
| Oct-02-20 | Initiated | Deutsche Bank | Buy |
| Mar-13-20 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-20-20 | Initiated | Goldman | Buy |
| Nov-19-19 | Initiated | CLSA | Buy |
| Oct-23-19 | Reiterated | BofA/Merrill | Buy |
| Jul-05-19 | Initiated | Macquarie | Outperform |
View All
Hutchmed China Limited Adr Stock (HCM) Latest News
[6-K] HUTCHMED (China) Ltd Current Report (Foreign Issuer) | HCM SEC FilingForm 6-K - Stock Titan
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Fanregratinib in Second-Line Intrahepatic Cholangiocarcinoma - GlobeNewswire Inc.
REGHutchmed China LtdBlocklisting Six Monthly Return - TradingView — Track All Markets
HUTCHMED (NASDAQ:HCM) Sees Strong Trading VolumeTime to Buy? - MarketBeat
Brokerages Set HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Target Price at $20.88 - Defense World
HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
HUTCHMED Initiates Global Clinical Development of ATTC Candidate HMPL-A251 in Patients with Solid Tumors - GlobeNewswire
Bearish block trade of HUTCHMED(00013) 278.5K shares at $22.0, $6.127M turnover - AASTOCKS.com
Schroder Investment Management Group Has $38.82 Million Stock Holdings in HUTCHMED (China) Limited Sponsored ADR $HCM - MarketBeat
HUTCHMED Share Movement in the (LSE:HCM) Landscape and FTSE Aim 100 - Kalkine Media
Forge Global Holdings, Inc. (NYSE:FRGE) Receives $42.00 Average Price Target from Analysts - Defense World
Rep. Lisa C. McClain Sells Off Shares of Gartner, Inc. (NYSE:IT) - Defense World
HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Catalyst Funds Management Pty Ltd Sells 29,903 Shares of HUTCHMED (China) Limited Sponsored ADR $HCM - MarketBeat
ABN Amro Investment Solutions Invests $962,000 in HUTCHMED (China) Limited Sponsored ADR $HCM - MarketBeat
HMPL-A251 combines HER2 targeting with precision payload - BioWorld MedTech
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing - The Globe and Mail
Transcript : HUTCHMED Limited Presents at Deutsche Bank ADR Virtual Investor Conference 2025, Nov-04-2025 08 - MarketScreener
HUTCHMED (China) Limited (HCM) HUTCHMED (China) Limited Presents at Deutsche Bank ADR Virtual Investor Conference 2025Slideshow (NASDAQ:HCM) 2025-11-04 - Seeking Alpha
Hutchmed Strengthens Position Within FTSE AIM 100 Index Healthcare Sphere - Kalkine Media
HUTCHMED Announces Enrollment Completed of SAFFRON Global - GlobeNewswire
Hutchmed takes wraps off expanding oncology pipeline - Sharecast.com
Market news - investments.halifax.co.uk
RCSHutchmed China LtdUpdates from R&D Event - TradingView
HUTCHMED Highlights Pipeline and Business Progress at R&D Updates Event - The Manila Times
ETFs Investing in HUTCHMED (China) Limited Sponsored ADR Stocks - TradingView
CORRECTION -- International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 04, 2025 - The Manila Times
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 04, 2025 - Macau Business
International companies to host live webcasts at Deutsche - GlobeNewswire
HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Receives Average Rating of "Hold" from Brokerages - MarketBeat
Vanguard Personalized Indexing Management LLC Buys 4,773 Shares of Cleanspark, Inc. $CLSK - Defense World
Vanguard Personalized Indexing Management LLC Sells 354 Shares of Cathay General Bancorp $CATY - Defense World
Hutchmed upbeat on preclinical data for novel cancer therapy - Sharecast.com
HUTCHMED Highlights HMPL-A251 Data Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - The Manila Times
HUTCHMED Highlights HMPL-A251 Data Presented at the - GlobeNewswire
Allianz Asset Management GmbH Sells 80,000 Shares of HUTCHMED (China) Limited Sponsored ADR $HCM - MarketBeat
Will Can Fite Biopharma Ltd Sponsored ADR stock benefit from mergersQuarterly Risk Review & Risk Controlled Stock Alerts - Trung tâm Dự báo KTTV quốc gia
Working capital per share of HUTCHMED (China) Limited Sponsored ADR – LSE:0J7G - TradingView
Pfizer: CN Biopharma Sector Shows Astonishing Growth; US Drug Industry Must Collaborate with CN - AASTOCKS.com
HUTCHMED Highlights FRUSICA-2 Registration Trial Data to be Presented at the 2025 ESMO Congress - GlobeNewswire
HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Hutchmed China Limited Adr Stock (HCM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.49%
2.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):